Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

CymaBay Therapeutics Company Profile (NASDAQ:CBAY)

Consensus Ratings for CymaBay Therapeutics (NASDAQ:CBAY) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.33 (119.36% upside)

Analysts' Ratings History for CymaBay Therapeutics (NASDAQ:CBAY)
Show:
DateFirmActionRatingPrice TargetDetailsShare
2/18/2015Roth CapitalSet Price TargetBuy$16.00ViewTweet This Rating  Share This Rating on StockTwits
1/20/2015Stifel NicolausBoost Price TargetBuy$10.00 -> $15.00ViewTweet This Rating  Share This Rating on StockTwits
9/19/2014Roth CapitalInitiated CoverageBuy$14.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2014Stifel NicolausInitiated CoverageBuy$10.00ViewTweet This Rating  Share This Rating on StockTwits
8/15/2014Cowen and CompanyBoost Price TargetOutperform$9.00 -> $15.00ViewTweet This Rating  Share This Rating on StockTwits
8/1/2014Cowen and CompanyInitiated CoverageOutperform$9.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 3/29/2013 forward)